But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Merck (MRK)’s stock surged by 41%, driven not significantly by revenue but rather by increased profits and heightened ...

Ever wondered if Merck’s current share price actually reflects its real worth? You’re not alone, and uncovering value can make all the difference for your portfolio. Merck’s stock has jumped 18.4% ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Merck (MRK) has quietly pulled ahead of many pharma peers, with the stock climbing about 22% over the past month and 20% in ...

Merck (MRK) stock in focus as the company urges shareholders to reject a mini-tender offer which stands at a 25% discount to MRK share price on Nov. 7. Read more here.

The article " Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything " first appeared on MarketBeat.